Alzheimer Disease Clinical Trial
— HeartBEAMOfficial title:
Heartrate and Breathing Effects on Attention and Memory Preliminary Study
Verified date | April 2024 |
Source | University of Southern California |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In the current study, we will examine how daily paced breathing affects plasma amyloid beta levels and the rate of learning in older adults. Healthy adults aged 50-70 who meet all eligibility criteria will be invited to this study. Participants will be randomly assigned to one of the two conditions: 1) Daily memory and attention training followed by a paced breathing protocol designed to increase relaxation or 2) Daily memory and attention training followed by a paced breathing protocol to increase alertness. Participants will be asked to complete pre and post intervention cognitive testing online, engage in 10 weeks of daily brain training (starting Week 2) and 9 weeks of paced breathing (starting Week 3) at home. They will also be asked to come in for lab visits on Weeks 2, 7 and 12 to provide blood and urine samples to assess amyloid beta levels and to complete magnetic resonance imaging scans to assess perivascular space volume.
Status | Completed |
Enrollment | 91 |
Est. completion date | November 13, 2023 |
Est. primary completion date | November 6, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years to 70 Years |
Eligibility | Inclusion Criteria: - speak English fluently - between the age of 50-70 - healthy adult who weighs at least 110 pounds - non-pregnant and non-menstruating (for at least the past year) - normal or corrected-to-normal vision and hearing - have a home computer with a physical keyboard and have access to reliable internet - have an email account that you check regularly - have a phone that receives text messages - willing to provide a blood sample and a urine sample at three lab visits - willing to devote up to 60 minutes daily to the study for 12 weeks (in addition to lab visits) Exclusion Criteria: - have a disorder that would impede performing the breathing intervention (e.g., abnormal cardiac rhythm, heart disease including coronary artery disease, angina, and arrhythmia, cognitive impairment, dyspnea) - regularly practicing any relaxation, biofeedback, or breathing technique (e.g., meditation) for more than an hour a week - regularly played Lumosity games in the past 6 months - participated in heart rate biofeedback studies in the USC Emotion & Cognition Lab - have any conditions listed below that are not safe for MRI - Claustrophobia - Have worked as a machinist, metal worker, or in any profession or hobby grinding metal? - Have had an injury to the eye involving a metallic object (e.g., metallic slivers, shavings, or foreign body) - Cardiac pacemaker - Implanted cardiac defibrillator - Aneurysm clip or brain clip - Carotid artery vascular clamp - Neurostimulator - Insulin or infusion pump - Spinal fusion stimulator - Cochlear, otologic, ear tubes or ear implant - Prosthesis (eye/orbital, penile, etc.) - Implant held in place by a magnet - Heart valve prosthesis - Artificial limb or joint - Other implants in body or head - Electrodes (on body, head or brain) - Intravascular stents, filters - Shunt (spinal or intraventricular) - Vascular access port or catheters - IUD - Transdermal delivery system or other types of foil patches (e.g., Nitro, Nicotine, Birth control, etc.) that cannot be removed for MRI - Shrapnel, buckshot, or bullets - Tattooed eyeliner or eyebrows - Body piercing(s) that cannot be removed for MRI - Metal fragments (eye, head, ear, skin) - Internal pacing wires - Aortic clips - Metal or wire mesh implants - Wire sutures or surgical staples - Harrington rods (spine) - Bone/joint pin, screw, nail, wire, plate - Wig or toupee that cannot be removed for MRI - Hair implants that involve staples or metal - Hearing aid(s) that cannot be removed for MRI - Dentures or retainers that cannot be removed for MRI |
Country | Name | City | State |
---|---|---|---|
United States | University of Southern California | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of Southern California | University of California, Irvine |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in plasma pTau-181/tau ratio [ Time Frame: Measured from blood draws at lab visits on Weeks 2, 7, and 12 ] | We will conduct a time (Week 2, 7, 12) X condition ANOVA to test for a time X condition interaction with plasma pTau-181/tau ratio as the dependent variable (to assess group differences in change). | Measured from blood draws at lab visits on Weeks 2, 7, and 12 | |
Other | Change in urine Ab42 | We will conduct a time (Week 2, 7, 12) X condition ANOVA to test for a time X condition interaction with urine Ab42 as the dependent variable (to assess group differences in change). | Measured from urine samples at lab visits on Weeks 2, 7, and 12 | |
Primary | Change in plasma amyloid beta levels | We will compute an aggregate score based on both plasma Ab40 and Ab42 levels. This score will be compared for Week 2 (pre-intervention), Week 7 (during intervention) and Week 12 (post intervention). We will conduct a time (Week 2, 7, 12) X condition ANOVA to test for a time X condition interaction in plasma Ab levels (to assess group differences in change). | Measured from blood draws at lab visits on Weeks 2, 7, and 12 | |
Primary | Change in plasma Ab42/40 ratio [ Time Frame: Measured from blood draws at lab visits on Weeks 2, 7, and 12 ] | We will conduct a time (Week 2, 7, 12) X condition ANOVA to test for a time X condition interaction with plasma Ab42/40 ratio scores as the dependent variable (to assess group differences in change). | Measured from blood draws at lab visits on Weeks 2, 7, and 12 | |
Secondary | Change in brain perivascular space volume | We will test whether there are group differences in change in perivascular space volume | Measured from magnetic resonance imaging completed at lab visits on Weeks 2, 7, and 12 | |
Secondary | Change in hippocampal volume | We will test whether there are group differences in change in hippocampal volume | Measured from magnetic resonance imaging completed at lab visits on Weeks 2, 7, and 12 | |
Secondary | Brain training performance on 12 Lumosity games during the breathing intervention (controlling for brain training performance pre intervention) | We will compute a general learning factor across performance on all 12 games played daily during the intervention period (Weeks 3-11). We will also assess game performance in the pre-intervention Week 2 to provide a baseline performance measure for each participant and statistically account for it. | Pre intervention (daily during Week 2) and during intervention (daily during Weeks 3-11) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |